BioCryst Pharmaceuticals, Inc. has transferred rights to specific classes of compounds that act as inhibitors of proteins and enzymes in the complement system to 3- Dimensional Pharmaceuticals, Inc. (3DP), a wholly owned subsidiary of Johnson & Johnson. BioCryst will receive an initial payment from 3DP, and will receive royalties on any future sales of complement Read more about Biocryst And 3DP Complement Agreement[…]